{
    "eid": "2-s2.0-84937632315",
    "title": "Review of tenofovir use in HIV-infected children",
    "cover-date": "2015-04-21",
    "subject-areas": [
        {
            "$": "Microbiology (medical)",
            "@code": "2726"
        },
        {
            "$": "Infectious Diseases",
            "@code": "2725"
        },
        {
            "$": "Pediatrics",
            "@code": "2735"
        }
    ],
    "keywords": [
        "children",
        "HIV",
        "tenofovir"
    ],
    "authors": [
        "Linda Aurpibul"
    ],
    "citedby-count": 23,
    "ref-count": 92,
    "ref-list": [
        "Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: A 10-year follow-up study",
        "Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adults",
        "Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): Investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir",
        "Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells",
        "Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients",
        "Viread: Highlight for Prescribing Information (Revised: October2013).",
        "Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial",
        "Atripla: Highlight of Prescribing Information.",
        "Complera: Highlight of Prescribing Information",
        "Stribild: Highlight of Prescribing Information.",
        "Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: Self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence",
        "Predictors of antiretroviral medication adherence among a diverse cohort of adolescents with HIV",
        "Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults",
        "Single-Dose and Steady-State Pharmacokinetics of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Children",
        "19th Conference on Retrovirus and Opportunistic Infection (CROI 2012)",
        "Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir",
        "Tenofovir disoproxil fumarate: Clinical pharmacology and pharmacokinetics",
        "Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients",
        "Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection",
        "Population pharmacokinetics of tenofovir in HIV-1-infected pediatric patients",
        "Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents.",
        "Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients",
        "20th Conference on Retrovirus and Opportunistic Infection (CROI 2013), March 3-6",
        "Effect of tenofovir on didanosine absorption in patients with HIV",
        "Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults",
        "Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine",
        "Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine",
        "High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen",
        "Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients",
        "Product Monograph Tenofovir Disoproxil Fumarate Tablets 300 Mg",
        "Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples",
        "6th Conference in HIV Pathogenesis and Treatment",
        "19th International AIDS Conference",
        "Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy",
        "Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: Final results",
        "Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - A 96-week analysis",
        "Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial",
        "Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: Simplification of combination treatment in HIV-1-infected children (PENTA-13)",
        "HLA-B*5701 screening for hypersensitivity to abacavir",
        null,
        "Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population",
        "Treatment if Children Living with HIV.",
        "A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: The HIV STAR study",
        "Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection",
        "A randomized study of tenofovir disoproxil fumarate in treatment- experienced HIV-1 infected adolescents",
        "Modulation of K65R selection by zidovudine inclusion: Analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (Study COL40263)",
        "Food and Drug Administration Approves New Formulations of Viread\u00ae for Use by Children Living with HIV",
        "A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression",
        "Technical Update on Treatment Optimization: Use of Tenofovir Disoproxil Fumarate in HIV-infected Children and Adolescents Aged 2-18 Years: A Public Health Perspective",
        "Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children",
        "Consolidated Guideline on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection; Reco Mmendations for A Public Healt H Approach",
        "Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in hiv-infected patients",
        "Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy",
        "The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: The first 4 years",
        "Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa",
        "Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland",
        "Adverse events experienced by three children taking tenofovir and didanosine in combination",
        "Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors",
        "Tenofovir treatment duration predicts proteinuria in a multiethnic united states cohort of children and adolescents with perinatal HIV-1 infection",
        "Renal safety of tenofovir in HIV-infected children: A prospective, 96-week longitudinal study",
        "Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: A nested case-control study",
        "Renal Tubular Dysfunction Associated with Tenofovir Therapy: Report of 7 Cases",
        "Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir",
        "Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: A 60-month follow-up study",
        "20th Conference on Retroviruses & Opportunistic Infections",
        "Bone health in children and adolescents with perinatal HIV infection",
        "Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents",
        "Insights into material and structural basis of bone fragility from diseases associated with fractures: How determinants of the biomechanical properties of bone are compromised by disease",
        "Bone mineral content in girls perinatally infected with HIV",
        "Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045",
        "Prevalence and risk factors of low bone mineral density among perinatally HIV-infected thai adolescents receiving antiretroviral therapy",
        "Factors associated with low bone mineral density in a Brazilian cohort of vertically HIV-infected adolescents",
        "Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: Impact on bone mineral density in HIV-infected children",
        "The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-na\u00efve HIV-1-infected patients",
        "Pediatr Infect Dis J.",
        "A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children",
        "Decreased Bone Mineral Density with Off-Label Use of Tenofovir in Children and Adolescents Infected with Human Immunodeficiency Virus",
        "Hepatitis B in the HIV-coinfected patient",
        "Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort",
        "Epidemiology, diagnosis and treatment of chronic hepatitis B in HIV-infected patients (EPIB 2005 STUDY)"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chiang Mai",
            "affilname": "Chiang Mai University",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}